Vita：武汉大学蓝柯团队发现克服癌症治疗耐药性的新靶点，并发现候选药物

Core Viewpoint - The research highlights the role of mitochondrial RNA (mtRNA) in activating the immune system during chemotherapy and identifies the PNPT1 protein as a key regulator in overcoming therapeutic resistance in cancer treatment [4][16]. Group 1: Mechanism of Immune Activation - Chemotherapy activates the immune system by releasing "danger signals" such as nuclear DNA, which triggers the cGAS-STING immune pathway [6]. - The new study reveals that chemotherapy also prompts mitochondria to release mitochondrial double-stranded RNA (mt-dsRNA), activating the MAVS pathway, a more universal immune response mechanism [6][5]. Group 2: Tumor Resistance Mechanism - Tumor cells counteract immune activation by upregulating PNPT1, a protein that degrades mitochondrial RNA, effectively destroying the "danger signals" before they can activate the immune system [8][9]. - High levels of PNPT1 in various cancers correlate with poor patient prognosis and weaker immune responses, contributing to chemotherapy and immunotherapy resistance [9][8]. Group 3: Proposed Treatment Strategy - The research proposes a combined treatment strategy: 1. "Internal" approach - Inhibiting PNPT1 using Lanatoside C, an FDA-approved drug, to allow the production of "danger signals" [10]. 2. "External" approach - Using BH3 mimetics to open channels in the mitochondrial membrane, facilitating the release of mt-dsRNA into the cytoplasm [10]. - The combination of these two approaches has shown significant synergistic effects in mouse tumor models, inhibiting tumor growth and extending survival [13]. Group 4: Significance and Future Prospects - This research offers new hope for cancer patients facing treatment resistance, suggesting that the combined approach could lead to breakthroughs in cancer therapy [15]. - The identification of PNPT1 as a target for overcoming immune evasion provides a new avenue for therapeutic development, with the potential for faster clinical translation due to the use of existing drugs [16].